Reduced median EFS (0.85 months [95%-CI: 0.23–7.10] vs. 6.84 months [95%-CI: 4.67–9.70], HR: 2.77 [95%-CI: 1.40–5.47], Cox regression p = 0.003, Fig. 4C) and OS (4.78 months [95%-CI: 0.72–8.84] vs. 14.10 months [95%-CI:12.06–19.86], HR: 3.18 [95%-CI: 1.60–6.30], Cox regression p = 0.001, Fig. 4D) was also found for EM AML patients with mutated IKZF1 compared to wildtype EM AML patients. Here, IKZF1 is linked to erythema multiforme.